While clinical guidelines provide recommendations to assist clinicians in making optimal treatment decisions for patients at all stages of disease, owing to the lack of rigorous evidence for most treatment modalities, there is no set standard of care treatment for patients with hidradenitis suppurativa. Therefore, both the North American clinical management guidelines and the European S1 guideline for the treatment of hidradenitis suppurativa recommend an individualized approach to treatment based on the subjective impact of the disease on the patient and the objective severity determined by the physician (eg, Hurley clinical staging classification).
Local excision coupled with systemic treatment is not the first-line approach to treating patients with hidradenitis suppurativa at all stages of disease, but rather is typically reserved for patients with severe and chronic disease.
Medical management of hidradenitis suppurativa is typically recommended in the early stages of disease.
Systemic biologics (adalimumab/infliximab) are not recommended as a first-line treatment for patients with mild to moderate hidradenitis suppurativa. Systemic biologics are typically reserved for patients with treatment-resistant, moderate to severe hidradenitis suppurativa.
Medscape © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: William D. James. Fast Five Quiz: Hidradenitis Suppurativa - Medscape - Nov 05, 2019.